ade-benchmark-corpus/ade_corpus_v2 · Datasets at Hugging Face

text stringlengths 7 742	label class label 2 classes
OBJECTIVE: To report 2 cases of serotonin syndrome with serious extrapyramidal movement disorders occurring when metoclopramide was coadministered with sertraline or venlafaxine.	1Related
OBJECTIVE: To report 2 cases of serotonin syndrome with serious extrapyramidal movement disorders occurring when metoclopramide was coadministered with sertraline or venlafaxine.	1Related
OBJECTIVE: To report 2 cases of serotonin syndrome with serious extrapyramidal movement disorders occurring when metoclopramide was coadministered with sertraline or venlafaxine.	1Related
Serotonin syndrome caused by selective serotonin reuptake-inhibitors-metoclopramide interaction.	1Related
She was administered metoclopramide because of nausea and, within 2 hours, developed agitation, dysarthria, diaphoresis, and a movement disorder.	1Related
She was administered metoclopramide because of nausea and, within 2 hours, developed agitation, dysarthria, diaphoresis, and a movement disorder.	1Related
She was administered metoclopramide because of nausea and, within 2 hours, developed agitation, dysarthria, diaphoresis, and a movement disorder.	1Related
She was administered metoclopramide because of nausea and, within 2 hours, developed agitation, dysarthria, diaphoresis, and a movement disorder.	1Related
She was admitted following a fall and, after being given metoclopramide, developed movement disorder and a period of unresponsiveness.	1Related
She was admitted following a fall and, after being given metoclopramide, developed movement disorder and a period of unresponsiveness.	1Related
A patient suffering from a rare enzyme deficiency developed a malignant neuroleptic syndrome after having been treated with one single dose of haloperidol.	1Related
BACKGROUND: reports on delated cutaneous reactions to captopril have been seldom reported.	1Related
Captopril is an angiotensin-converting enzyme (ACE) inhibitor and their cutaneous side-effects are documented, but little has been published concerning the usefulness of patch test when they occur.	1Related
Dermatitis to captopril.	1Related
We presented the case of a patient who developed a cutaneous reaction induced by captopril with positive patch test.	1Related
A 62-year-old Caucasian man with atrial fibrillation who was taking warfarin reported an episode of hematochezia; his international normalized ratio (INR) was 1.74.	1Related
Warfarin-associated bleeding complication saved life.	1Related
Warfarin-associated bleeding generally is considered deleterious; however, in our patient it unmasked an early stage of colon cancer and thus may have saved the patient's life.	1Related
A case of polymyositis with dilated cardiomyopathy associated with interferon alpha treatment for hepatitis B.	1Related
A case of polymyositis with dilated cardiomyopathy associated with interferon alpha treatment for hepatitis B.	1Related
In this case, interferon alpha induced polymyositis and cardiomyopathy is diagnosed in a 33-yr-old male patient with history of chronic hepatitis B.	1Related
In this case, interferon alpha induced polymyositis and cardiomyopathy is diagnosed in a 33-yr-old male patient with history of chronic hepatitis B.	1Related
Polymyositis is a rare complication of interferon alpha treatment as a result of immune-modulating role of the drug itself.	1Related
To treat hepatitis B, interferon alpha was administered until the proximal muscle weakness developed.	1Related
Long-term follow-up after neoplastic seeding complicating percutaneous ethanol injection for treatment of hepatocellular carcinoma.	1Related
We describe a case of subcutaneous metastasis along the needle track after percutaneous ethanol injection (PEI) for treatment of hepatocellular carcinoma.	1Related
Aggressive endometrial carcinoma in a breast cancer patient treated with tamoxifen with normal transvaginal ultrasonography.	1Related
Since tamoxifen therapy can induce endometrial disorders, surveillance schemes of women taking tamoxifen have been recommended.	1Related
Since tamoxifen therapy can induce endometrial disorders, surveillance schemes of women taking tamoxifen have been recommended.	1Related
We described a very atypical case of a high stage, high grade endometrial cancer associated with tamoxifen in a 64-year-old woman with a past history of breast cancer.	1Related
Beginning ductopenia was present in two, suggesting that itraconazole might be responsible for the occurrence of prolonged drug-induced cholangiopathy.	1Related
Beginning ductopenia was present in two, suggesting that itraconazole might be responsible for the occurrence of prolonged drug-induced cholangiopathy.	1Related
CONCLUSIONS: Itraconazole-induced liver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts, possibly leading to ductopenia.	1Related
CONCLUSIONS: Itraconazole-induced liver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts, possibly leading to ductopenia.	1Related
CONCLUSIONS: Itraconazole-induced liver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts, possibly leading to ductopenia.	1Related
CONCLUSIONS: Itraconazole-induced liver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts, possibly leading to ductopenia.	1Related
Hepatotoxicity related to itraconazole: report of three cases.	1Related
METHODS: Three patients with apparent itraconazole-induced liver injury were studied.	1Related
The occurrence of acute hepatitis is best known for ketoconazole.	1Related
We report on three patients who developed acute liver damage during therapy with itraconazole, and in whom liver biopsy specimens were obtained.	1Related
We suggest that itraconazole should be added to the list of drugs that may be responsible for a drug-induced vanishing bile duct syndrome.	1Related
With itraconazole, hepatotoxic reactions have only very rarely been reported, and histologic data are lacking.	1Related
Thrombotic stroke associated with the use of porcine factor VIII in a patient with acquired haemophilia.	1Related
We have recently encountered a patient with acquired haemophilia who developed a thrombotic left middle cerebral artery distribution stroke while being treated with pFVIII.	1Related
We speculate that platelet activation induced by pFVIII may have contributed to thrombosis and suggest that pFVIII be used with caution in elderly patients with pre-existing cardiovascular risk factors.	1Related
Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases.	1Related
Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases.	1Related
There have been more than 20 observations of the appearance or aggravation of this granulomatosis with interferon alfa and more recently with the combination of interferon alfa plus ribavirin.	1Related
There have been more than 20 observations of the appearance or aggravation of this granulomatosis with interferon alfa and more recently with the combination of interferon alfa plus ribavirin.	1Related
There have been more than 20 observations of the appearance or aggravation of this granulomatosis with interferon alfa and more recently with the combination of interferon alfa plus ribavirin.	1Related
We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin.	1Related
We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin.	1Related
CONCLUSIONS: Although mirtazapine offers clinicians a combination of strong efficacy and good safety, we suggest bearing SS in mind when prescribing this drug, especially in frail, elderly patients with underlying chronic conditions.	1Related
DISCUSSION: A review of the cases of SS with implication of mirtazapine as the cause was performed.	1Related
OBJECTIVE: To document a case of serotonin syndrome (SS) associated with mirtazapine monotherapy, review the previously reported cases of SS associated with this tetracyclic antidepressant, and discuss the possible pathogenic mechanisms leading to this serious adverse drug reaction.	1Related
OBJECTIVE: To document a case of serotonin syndrome (SS) associated with mirtazapine monotherapy, review the previously reported cases of SS associated with this tetracyclic antidepressant, and discuss the possible pathogenic mechanisms leading to this serious adverse drug reaction.	1Related
Severe serotonin syndrome induced by mirtazapine monotherapy.	1Related
Pulmonary toxicity secondary to procarbazine.	1Related
A 64-year-old man presented with proteinuria during postoperative interferon (IFN)-beta therapy against malignant melanoma.	1Related
Minimal change nephrotic syndrome developing during postoperative interferon-beta therapy for malignant melanoma.	1Related
To our knowledge this is the first report that demonstrates histological abnormalities of the glomerulus associated with postoperative IFN-beta therapy for the malignant melanoma.	1Related
The authors report two cases of delayed elimination of methotrexate in patients receiving ciprofloxacin, with severe toxicity.	1Related
The authors report two cases of delayed elimination of methotrexate in patients receiving ciprofloxacin, with severe toxicity.	1Related
The authors report two cases of delayed elimination of methotrexate in patients receiving ciprofloxacin, with severe toxicity.	1Related
CONCLUSIONS: Clinicians should be aware of the possible association of thrombocytopenia with lansoprazole and discontinue the drug if thrombocytopenia becomes apparent.	1Related
DISCUSSION: After exclusion of other causes, the onset of thrombocytopenia after administration of lansoprazole, the resolution of the adverse reaction after discontinuation of the drug, and the fact that no other medicines were introduced during this time frame lead us to believe that this was most likely an idiosyncratic thrombocytopenic response to lansoprazole.	1Related
DISCUSSION: After exclusion of other causes, the onset of thrombocytopenia after administration of lansoprazole, the resolution of the adverse reaction after discontinuation of the drug, and the fact that no other medicines were introduced during this time frame lead us to believe that this was most likely an idiosyncratic thrombocytopenic response to lansoprazole.	1Related
He was started on oral lansoprazole 60 mg twice daily and, on hospital day 2, his platelet count decreased to 102 x 10(3)/mm(3); on hospital day 3, the platelet count was 36 x 10(3)/mm(3).	1Related
Lansoprazole-induced thrombocytopenia.	1Related
OBJECTIVE: To describe a case of thrombocytopenia associated with the administration of lansoprazole.	1Related
To date, this is the first reported case of what appears to be isolated thrombocytopenia associated with lansoprazole.	1Related
Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review.	1Related
The most common side effects associated with amifostine are nausea, vomiting, hypotension, hypocalcemia and allergic reactions.	1Related
The most common side effects associated with amifostine are nausea, vomiting, hypotension, hypocalcemia and allergic reactions.	1Related
The most common side effects associated with amifostine are nausea, vomiting, hypotension, hypocalcemia and allergic reactions.	1Related
The most common side effects associated with amifostine are nausea, vomiting, hypotension, hypocalcemia and allergic reactions.	1Related
The most common side effects associated with amifostine are nausea, vomiting, hypotension, hypocalcemia and allergic reactions.	1Related
The patient suffered a life-threatening anaphylactoid reaction to amifostine.	1Related
Agranulocytosis during clozapine therapy.	1Related
Granulocytopenia and agranulocytosis are considered among the most dangerous adverse effects of clozapine.	1Related
Granulocytopenia and agranulocytosis are considered among the most dangerous adverse effects of clozapine.	1Related
The female patient received clozapine in a daily dose of 400 mg, which induced agranulocytosis after 2 months.	1Related
The male patient was treated with 225-mg/day clozapine and the time to the diagnosis of agranulocytosis was 6 weeks.	1Related
A 53-year-old man developed NMS without rigidity while taking olanzapine.	1Related
Atypical neuroleptic malignant syndrome associated with olanzapine.	1Related
CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.	1Related
CONCLUSIONS: Priapism is an uncommon but potentially serious adverse effect of zuclopenthixol that practitioners, as with many other antipsychotics, should be aware of.	1Related
DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.	1Related
OBJECTIVE: To present a single case of zuclopenthixol-induced priapism and a literature review.	1Related
Priapism associated with zuclopenthixol.	1Related
The capacity of zuclopenthixol to induce priapism is thought to be due to its antagonist activity on alpha-adrenergic receptors.	1Related
After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.	1Related
Metamizole, a nonsteroidal antiinflammatory agent, is prohibited in the United States because of the risk of agranulocytosis but is widely used in Mexico and other countries.	1Related
Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome.	1Related
We describe a patient who developed HUS after treatment with mitomycin C (total dose 144 mg/m2) due to a carcinoma of the ascending colon.	1Related
Levofloxacin-induced toxic epidermal necrolysis in an elderly patient.	1Related
To our knowledge, this case is the first published report of levofloxacin-induced TEN.	1Related
A 31-year-old female developed multiple episodes of grand mal seizures after combination chemotherapy with cisplatin, vinblastine and bleomycin for germ cell ovarian cancer stage Ic.	1Related
A 31-year-old female developed multiple episodes of grand mal seizures after combination chemotherapy with cisplatin, vinblastine and bleomycin for germ cell ovarian cancer stage Ic.	1Related
A 31-year-old female developed multiple episodes of grand mal seizures after combination chemotherapy with cisplatin, vinblastine and bleomycin for germ cell ovarian cancer stage Ic.	1Related

OBJECTIVE: To report 2 cases of serotonin syndrome with serious extrapyramidal movement disorders occurring when metoclopramide was coadministered with sertraline or venlafaxine.

1Related

OBJECTIVE: To report 2 cases of serotonin syndrome with serious extrapyramidal movement disorders occurring when metoclopramide was coadministered with sertraline or venlafaxine.

1Related

OBJECTIVE: To report 2 cases of serotonin syndrome with serious extrapyramidal movement disorders occurring when metoclopramide was coadministered with sertraline or venlafaxine.

1Related

Serotonin syndrome caused by selective serotonin reuptake-inhibitors-metoclopramide interaction.

1Related

She was administered metoclopramide because of nausea and, within 2 hours, developed agitation, dysarthria, diaphoresis, and a movement disorder.

1Related

She was administered metoclopramide because of nausea and, within 2 hours, developed agitation, dysarthria, diaphoresis, and a movement disorder.

1Related

She was administered metoclopramide because of nausea and, within 2 hours, developed agitation, dysarthria, diaphoresis, and a movement disorder.

1Related

She was administered metoclopramide because of nausea and, within 2 hours, developed agitation, dysarthria, diaphoresis, and a movement disorder.

1Related

She was admitted following a fall and, after being given metoclopramide, developed movement disorder and a period of unresponsiveness.

1Related

She was admitted following a fall and, after being given metoclopramide, developed movement disorder and a period of unresponsiveness.

1Related

A patient suffering from a rare enzyme deficiency developed a malignant neuroleptic syndrome after having been treated with one single dose of haloperidol.

1Related

BACKGROUND: reports on delated cutaneous reactions to captopril have been seldom reported.

1Related

Captopril is an angiotensin-converting enzyme (ACE) inhibitor and their cutaneous side-effects are documented, but little has been published concerning the usefulness of patch test when they occur.

1Related

Dermatitis to captopril.

1Related

We presented the case of a patient who developed a cutaneous reaction induced by captopril with positive patch test.

1Related

A 62-year-old Caucasian man with atrial fibrillation who was taking warfarin reported an episode of hematochezia; his international normalized ratio (INR) was 1.74.

1Related

Warfarin-associated bleeding complication saved life.

1Related

Warfarin-associated bleeding generally is considered deleterious; however, in our patient it unmasked an early stage of colon cancer and thus may have saved the patient's life.

1Related

A case of polymyositis with dilated cardiomyopathy associated with interferon alpha treatment for hepatitis B.

1Related

A case of polymyositis with dilated cardiomyopathy associated with interferon alpha treatment for hepatitis B.

1Related

In this case, interferon alpha induced polymyositis and cardiomyopathy is diagnosed in a 33-yr-old male patient with history of chronic hepatitis B.

1Related

In this case, interferon alpha induced polymyositis and cardiomyopathy is diagnosed in a 33-yr-old male patient with history of chronic hepatitis B.

1Related

Polymyositis is a rare complication of interferon alpha treatment as a result of immune-modulating role of the drug itself.

1Related

To treat hepatitis B, interferon alpha was administered until the proximal muscle weakness developed.

1Related

Long-term follow-up after neoplastic seeding complicating percutaneous ethanol injection for treatment of hepatocellular carcinoma.

1Related

We describe a case of subcutaneous metastasis along the needle track after percutaneous ethanol injection (PEI) for treatment of hepatocellular carcinoma.

1Related

Aggressive endometrial carcinoma in a breast cancer patient treated with tamoxifen with normal transvaginal ultrasonography.

1Related

Since tamoxifen therapy can induce endometrial disorders, surveillance schemes of women taking tamoxifen have been recommended.

1Related

Since tamoxifen therapy can induce endometrial disorders, surveillance schemes of women taking tamoxifen have been recommended.

1Related

We described a very atypical case of a high stage, high grade endometrial cancer associated with tamoxifen in a 64-year-old woman with a past history of breast cancer.

1Related

Beginning ductopenia was present in two, suggesting that itraconazole might be responsible for the occurrence of prolonged drug-induced cholangiopathy.

1Related

Beginning ductopenia was present in two, suggesting that itraconazole might be responsible for the occurrence of prolonged drug-induced cholangiopathy.

1Related

CONCLUSIONS: Itraconazole-induced liver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts, possibly leading to ductopenia.

1Related

CONCLUSIONS: Itraconazole-induced liver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts, possibly leading to ductopenia.

1Related

CONCLUSIONS: Itraconazole-induced liver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts, possibly leading to ductopenia.

1Related

CONCLUSIONS: Itraconazole-induced liver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts, possibly leading to ductopenia.

1Related

Hepatotoxicity related to itraconazole: report of three cases.

1Related

METHODS: Three patients with apparent itraconazole-induced liver injury were studied.

1Related

The occurrence of acute hepatitis is best known for ketoconazole.

1Related

We report on three patients who developed acute liver damage during therapy with itraconazole, and in whom liver biopsy specimens were obtained.

1Related

We suggest that itraconazole should be added to the list of drugs that may be responsible for a drug-induced vanishing bile duct syndrome.

1Related

With itraconazole, hepatotoxic reactions have only very rarely been reported, and histologic data are lacking.

1Related

Thrombotic stroke associated with the use of porcine factor VIII in a patient with acquired haemophilia.

1Related

We have recently encountered a patient with acquired haemophilia who developed a thrombotic left middle cerebral artery distribution stroke while being treated with pFVIII.

1Related

We speculate that platelet activation induced by pFVIII may have contributed to thrombosis and suggest that pFVIII be used with caution in elderly patients with pre-existing cardiovascular risk factors.

1Related

Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases.

1Related

Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases.

1Related

There have been more than 20 observations of the appearance or aggravation of this granulomatosis with interferon alfa and more recently with the combination of interferon alfa plus ribavirin.

1Related

There have been more than 20 observations of the appearance or aggravation of this granulomatosis with interferon alfa and more recently with the combination of interferon alfa plus ribavirin.

1Related

There have been more than 20 observations of the appearance or aggravation of this granulomatosis with interferon alfa and more recently with the combination of interferon alfa plus ribavirin.

1Related

We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin.

1Related

We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin.

1Related

CONCLUSIONS: Although mirtazapine offers clinicians a combination of strong efficacy and good safety, we suggest bearing SS in mind when prescribing this drug, especially in frail, elderly patients with underlying chronic conditions.

1Related

DISCUSSION: A review of the cases of SS with implication of mirtazapine as the cause was performed.

1Related

OBJECTIVE: To document a case of serotonin syndrome (SS) associated with mirtazapine monotherapy, review the previously reported cases of SS associated with this tetracyclic antidepressant, and discuss the possible pathogenic mechanisms leading to this serious adverse drug reaction.

1Related

OBJECTIVE: To document a case of serotonin syndrome (SS) associated with mirtazapine monotherapy, review the previously reported cases of SS associated with this tetracyclic antidepressant, and discuss the possible pathogenic mechanisms leading to this serious adverse drug reaction.

1Related

Severe serotonin syndrome induced by mirtazapine monotherapy.

1Related

Pulmonary toxicity secondary to procarbazine.

1Related

A 64-year-old man presented with proteinuria during postoperative interferon (IFN)-beta therapy against malignant melanoma.

1Related

Minimal change nephrotic syndrome developing during postoperative interferon-beta therapy for malignant melanoma.

1Related

To our knowledge this is the first report that demonstrates histological abnormalities of the glomerulus associated with postoperative IFN-beta therapy for the malignant melanoma.

1Related

The authors report two cases of delayed elimination of methotrexate in patients receiving ciprofloxacin, with severe toxicity.

1Related

The authors report two cases of delayed elimination of methotrexate in patients receiving ciprofloxacin, with severe toxicity.

1Related

The authors report two cases of delayed elimination of methotrexate in patients receiving ciprofloxacin, with severe toxicity.

1Related

CONCLUSIONS: Clinicians should be aware of the possible association of thrombocytopenia with lansoprazole and discontinue the drug if thrombocytopenia becomes apparent.

1Related

DISCUSSION: After exclusion of other causes, the onset of thrombocytopenia after administration of lansoprazole, the resolution of the adverse reaction after discontinuation of the drug, and the fact that no other medicines were introduced during this time frame lead us to believe that this was most likely an idiosyncratic thrombocytopenic response to lansoprazole.

1Related

DISCUSSION: After exclusion of other causes, the onset of thrombocytopenia after administration of lansoprazole, the resolution of the adverse reaction after discontinuation of the drug, and the fact that no other medicines were introduced during this time frame lead us to believe that this was most likely an idiosyncratic thrombocytopenic response to lansoprazole.

1Related

He was started on oral lansoprazole 60 mg twice daily and, on hospital day 2, his platelet count decreased to 102 x 10(3)/mm(3); on hospital day 3, the platelet count was 36 x 10(3)/mm(3).

1Related

Lansoprazole-induced thrombocytopenia.

1Related

OBJECTIVE: To describe a case of thrombocytopenia associated with the administration of lansoprazole.

1Related

To date, this is the first reported case of what appears to be isolated thrombocytopenia associated with lansoprazole.

1Related

Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review.

1Related